Walmart halts H-1B visa offers amid Trump’s $100,000 fee increase - Bloomberg
Intellia Therapeutics Inc. (NTLA) stock reached a 52-week high, hitting a price of 27.05 USD, with an impressive 242% surge over the past six months. According to InvestingPro data, the company maintains a healthy balance sheet with more cash than debt and a strong current ratio of 5.19. Over the past year, the company’s stock has experienced a positive change of 19.74%, reflecting investor confidence and potential growth prospects in the biotechnology sector. This milestone highlights the company’s ongoing advancements and strategic initiatives in the field of genome editing and therapeutic development. While the company’s revenue grew 15% in the last twelve months, InvestingPro analysis reveals some challenges, including rapid cash burn and weak profit margins. Investors are closely watching Intellia’s progress as it continues to navigate the competitive landscape of biotech innovation. Get access to 13 additional exclusive ProTips and comprehensive analysis with an InvestingPro subscription.
In other recent news, Intellia Therapeutics has reported significant developments in its gene therapy programs. The company announced that its investigational gene therapy, nexiguran ziclumeran (nex-z), showed sustained reduction of transthyretin (TTR) protein levels in patients with hereditary ATTR amyloidosis with polyneuropathy, maintaining a mean reduction of at least 90% over three years. Additionally, Intellia plans to present long-term data from its Phase 1 trial of nex-z at the 5th International ATTR Amyloidosis Meeting in Italy.
Intellia’s stock rating was upgraded by Citizens from Market Perform to Market Outperform, with a new price target of $33.00, reflecting optimism about the company’s hereditary angioedema (HAE) therapy prospects. H.C. Wainwright also raised its price target for Intellia to $30.00, maintaining a Buy rating, citing the rapid enrollment of approximately 60 patients in the pivotal Phase 3 HAELO trial. Citizens JMP reiterated its Market Perform rating, noting the swift completion of Intellia’s Phase 3 study as a positive sign of interest in their gene-editing treatment for HAE. These developments highlight the ongoing interest and advancements in Intellia’s therapeutic programs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.